Clinical Trial Update: Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL [Phase 3]

View source ↗

Summary

A multicenter Phase 3 trial evaluating fixed-dose nivolumab (40 mg) in combination with chemo-immunotherapy for newly diagnosed primary mediastinal lymphoma, cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Primary Mediastinal Lymphoma | Phase 3 | Status: RECRUITING